Endocrine Abstracts

Excessive expression of CyD1 in CCND1 gene increase G1-S phase transition and cellular proliferation. In various tumor types and of the few studies of pituitary adenomas, over expression of CyD1 or amplification in the locus of CCND1 gene, have been demonstrated. In this study, we aimed to investigate the effect of cyclin D1 gene polymorphism on tumor formation in prolactinoma patients.

A hundred and thirteen patients and 108 age and gender matched control subjects with the diagnosis of prolactinoma were included in the study.

Male/female ratio was 27/86 and mean age of diagnosis was 34.4±10.0 years in 113 patients included to the study. Mean age of diagnosis was found as 40.3±12.6 years in the male and 32.6±8.3 in the female patients. A and G allele rates were found as 41.7 and 58.3% in the controls, while these rates were 61.1 and 39.9% in the patients; respectively. GA genotype was the the most common genotype subgroup in the control and patient groups by 40.7 and 51.3%; respectively, while GG genotype was found significantly lower in the patient group compared to the controls. Differences between the groups in terms of the allele rates and genotype distribution were found statistically significant.

Rate of AA genotype and A allele incidence were seen to be significantly higher in the prolactinoma patients than in the controls. Genotype distribution and allele incidences of 113 cases (68 noninvasive, 45 invasive) are given in Table 1 with the values from the previous studies. Accordingly, the rate of AA genotype and A allele incidence are seen higher compared to other studies. This high rate compared to other studies may be resulted from the differences in the measurement methods as well as in the time of the studies. From this point, the rate of increase in A alleles supports the concept of the increase rates may be related to the increase in the incidence of prolactinomas, and Cycline D1 protein may play a role in the occurrence of prolactinomas.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.